AGP8696W1045
© BusinessWire
04.01.2026
SVA
LISTED
NASDAQ
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP...
Themefolio
Profiler
Peergroup
© BusinessWire
04.01.2026
SVA
LISTED
NASDAQ
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq’s Listing...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
SVA
LISTED
NASDAQ
Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the Boar...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
12.11.2025
SVA
LISTED
NASDAQ
Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
News Preview
BOSTON, Nov. 12, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared by the bo...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
12.11.2025
SVA
LISTED
NASDAQ
Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
News Preview
BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared by the bo...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2025
SVA
LISTED
NASDAQ
Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
News Preview
BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared by the bo...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2025
SVA
LISTED
NASDAQ
/C O R R E C T I O N -- Heng Ren Partners/
News Preview
In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
Independent...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2025
SVA
LISTED
NASDAQ
Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
News Preview
BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared by the bo...
Themefolio
Profiler
Peergroup
© BusinessWire
10.07.2025
SVA
LISTED
NASDAQ
Newly Elected Directors of Sinovac Hold the First Board Meeting
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan an...
Themefolio
Profiler
Peergroup
© BusinessWire
09.07.2025
SVA
LISTED
NASDAQ
Sinovac Shareholders Vote to Remove Current Directors and Elect SAIF Partners Nominees to Board at Special Meeting
News Preview
SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), today announced that Sinovac Biotech Ltd. (“Sinovac” or the “Company”) shareholders voted to approve SAIF Partners’ proposals to remove the Company’s incumbent directors and to elect SAIF Partners’ slate of ten highly qualified director nominees to the Board of Directors (the “Board”) at Sino...
Themefolio
Profiler
Peergroup
© BusinessWire
09.07.2025
SVA
LISTED
NASDAQ
Appeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder Vote
News Preview
Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the Court of Appeals of the Eastern Caribbean Supreme Court granted a motion to stay the self-interested injunction s...
Themefolio
Profiler
Peergroup
© BusinessWire
02.07.2025
SVA
LISTED
NASDAQ
United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac
News Preview
Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long-term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the United States District Court of Massachusetts (“the Court”) granted Vivo’s motion for a preliminary injunction ag...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
02.07.2025
SVA
LISTED
NASDAQ
SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
News Preview
SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”) which beneficially owns approximately 15% of the Company’s outstanding common shares, today urged shareholders to immediately vote “FOR” the election of SAIF Partners’ ten highly qualified director candidates to...
Themefolio
Profiler
Peergroup
© BusinessWire
02.07.2025
SVA
LISTED
NASDAQ
CORRECTING and REPLACING SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
News Preview
Third paragraph, second sentence of release should read: These include the current Board’s failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac’s prior public accounting firm to resign in April, and it...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
SVA
LISTED
NASDAQ
SAIF Partners Sends Letter to Sinovac Shareholders
News Preview
SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to Sinovac shareholders regarding the current Board’s empty promises to shareholders, numerous failures overseeing the Company, and c...
Themefolio
Profiler
Peergroup
© BusinessWire
24.06.2025
SVA
LISTED
NASDAQ
SAIF Partners Sends Open Letter to Sinovac Shareholders Outlining Current Board’s Failure to Act in the Interests of Shareholders
News Preview
SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to its fellow Sinovac shareholders exposing the current Sinovac Board’s failure to act in the interest of all shareholders resulting...
Themefolio
Profiler
Peergroup
© BusinessWire
22.06.2025
SVA
LISTED
NASDAQ
Prime Success Issues Statement on New York State Court Decision Confirming Our Rights as Sinovac Shareholders – Including Right to Vote at Upcoming Special Meeting
News Preview
Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a statement in response to the decision by the United States District Court for the Southern D...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
SVA
LISTED
NASDAQ
SINOVAC Announces New Board Member
News Preview
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the “Board”) and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nomin...
Themefolio
Profiler
Peergroup
© BusinessWire
17.06.2025
SVA
LISTED
NASDAQ
Prime Success Sets the Record Straight Regarding Continued False and Misleading Statements from Sinovac Biotech’s Current Board
News Preview
Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a statement in response to the Company’s continued false, misleading and outright fabricated c...
Themefolio
Profiler
Peergroup
© BusinessWire
16.06.2025
SVA
LISTED
NASDAQ
SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board
News Preview
SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today announced that it has filed a definitive proxy statement for the election of ten director nominees to Sinovac’s Board of Directors (the “Board”) in...
Themefolio
Profiler
Peergroup
© BusinessWire
16.06.2025
SVA
LISTED
NASDAQ
SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders
News Preview
The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today disclosed that on June 12, 2025, Advantech/Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust...
Themefolio
Profiler
Peergroup
© BusinessWire
14.06.2025
SVA
LISTED
NASDAQ
Prime Success Responds to Sinovac Biotech’s False and Misleading Claims
News Preview
Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued the following letter in response to the Company’s recent false and misleading claims relating...
Themefolio
Profiler
Peergroup
© BusinessWire
13.06.2025
SVA
LISTED
NASDAQ
SINOVAC’s Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All Shareholders
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
SVA
LISTED
NASDAQ
Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company’s False and Misleading Claims
News Preview
Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% shareholder in Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today sent a letter to shareholders.
***
Dear Fellow Sinovac Shareholders,
We, Vivo Capital (“Vivo”), write to you as fellow...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
SVA
LISTED
NASDAQ
Prime Success Sends Letter to Sinovac Biotech Shareholders
News Preview
Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) with ownership of approximately 8% of the Company’s outstanding shares, today issued a letter to shareholders in connection with the upcoming Special Meeting of Shareholders (the...
Themefolio
Profiler
Peergroup
© BusinessWire
23.05.2025
SVA
LISTED
NASDAQ
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 16, 2025 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq Listing Rule 5250...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
SVA
LISTED
NASDAQ
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET....
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
SVA
LISTED
NASDAQ
SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the “Vivo group”) against the legitim...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
SVA
LISTED
NASDAQ
Vivo Capital Files Lawsuits to Protect Sinovac Shareholders from the New Board’s Value Destructive Actions
News Preview
Vivo Capital (“Vivo” or the “Firm”), a leading global investment firm focused exclusively on healthcare and life sciences, today announced multiple legal proceedings to challenge the irresponsible actions taken by the current Board of Directors of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”) under the control of the activist inve...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
SVA
LISTED
NASDAQ
SINOVAC Announces Decision to Declare Cash Dividend
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company’s board of directors (the “Board”) has decided to declare a special cash dividend of US$55.00 per common share (the “Dividend”). The Board expects to fund the Dividend from available cash reso...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
SVA
LISTED
NASDAQ
SINOVAC Announces New Board Member and Chairman of the Audit Committee
News Preview
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under N...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
SVA
LISTED
NASDAQ
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
News Preview
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
SVA
LISTED
NASDAQ
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
News Preview
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
SVA
LISTED
NASDAQ
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
News Preview
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
SVA
LISTED
NASDAQ
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
News Preview
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
SVA
LISTED
NASDAQ
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
News Preview
BOSTON, March 20, 2025 /CNW/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng...
Themefolio
Profiler
Peergroup
© BusinessWire
28.02.2025
SVA
LISTED
NASDAQ
SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order
News Preview
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) from the Privy Council following the previously announced Privy Council Judgment (the “Judgment”) which ruled, among others, that...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2025
SVA
LISTED
NASDAQ
SINOVAC Issues Statement Regarding Privy Council Judgment
News Preview
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
SVA
LISTED
NASDAQ
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
News Preview
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines against HFMD have yet b...
Themefolio
Profiler
Peergroup
© BusinessWire
16.08.2024
SVA
LISTED
NASDAQ
SINOVAC Reports Unaudited First Half of 2024 Financial Results
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2024.
First Half of 2024 Financial Summary
Sales for the six months ended June 30, 2024 were $121.3 million, compared to $140.4 million in...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
